chartexchange

Rein reports early Phase II data for inhaled IPF drug

Clinical Trials Arena | Nov 17, 2026 4:08 AM EST

Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03, for IPF.
The post Rein reports early Phase II data for inhaled IPF drug appeared first on Clinical Trials Arena .

Read original article